FindTrial
Sign In

The significance in prevention of acute exacerbations of IPF by oral administration of eight anabacteria

An observational study of the significance in prevention of acute exacerbations of IPF by oral administration of eight anabacteria

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-OOC-15005840
Enrollment
Unknown
Registered
2015-01-17
Start date
2015-01-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Idiopathic pulmonary fibrosis

Interventions

The immune-based treatment group :oral Broncho-Vaxom
no immunotherapeutic group :no immunomodulator treatment

Sponsors

Shanghai Pulmonary Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
50 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. The IPF patients conform to the bacteria of ATS/ERS/JRS/ALAT in 2011; 2. Ages from 50-80, male or female; 3. Good compliance, willing to come to our hospital for the follow-up observation according to the requirements of the scheme; 4. Be informed adequately about purpose, methods of the test and the possible discomfort. And signed the informed consent.

Exclusion criteria

Exclusion criteria: 1. The patients used to take amiodarone; 2. Allergy to Broncho-Vaxom; 3. Patients with malignant tumor; 4. Complicated with serious damage in other systems and organs; 5. Pregnant, breast-feeding period Women, plan of having a baby, cannot to take contraceptive measures.

Design outcomes

Primary

MeasureTime frame
acute acceleration;quality of life;the changes of chest HRCT;lung function;death;—

Countries

China

Contacts

Public ContactHuiping Li
liw2013@126.com+86 13817389991

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026